Ligand Pharmaceuticals (LGND) Shares Outstanding (Weighted Average) (2010 - 2026)

Ligand Pharmaceuticals has disclosed Shares Outstanding (Weighted Average) across 17 years of filings, most recently posting $19.9 million for Q1 2026.

• Shares Outstanding (Weighted Average) for Q1 2026 came in at $19.9 million, up 3.61% year-over-year; the trailing twelve-month figure through Mar 2026 was $19.9 million (up 3.61% YoY), and the FY2025 annual result was $19.3 million, up 5.73% from the prior year.
• Shares Outstanding (Weighted Average) came in at $19.9 million for Q1 2026 at Ligand Pharmaceuticals, up from $19.3 million in the prior quarter.
• In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $19.9 million in Q1 2026 to a low of $16.8 million in Q1 2022.
• The 5-year median for Shares Outstanding (Weighted Average) is $17.7 million (2024), against an average of $18.0 million.
• Across the five-year window, Shares Outstanding (Weighted Average) grew 1.03% in 2022 and grew 8.23% in 2025, its largest moves.
• Ligand Pharmaceuticals' Shares Outstanding (Weighted Average) stood at $16.9 million in 2022, then climbed by 2.55% to $17.3 million in 2023, then gained by 5.73% to $18.3 million in 2024, then climbed by 5.73% to $19.3 million in 2025, then grew by 2.82% to $19.9 million in 2026.
• The last three Shares Outstanding (Weighted Average) figures came in at $19.9 million (Q1 2026), $19.3 million (Q4 2025), and $19.4 million (Q3 2025), per Business Quant data.